P53 – Medxy AI

Unraveling MDM4 Haploinsufficiency: A Novel TP53-Dependent Mechanism Driving Bone Marrow Failure Syndromes

By MedXY 07/17/2026

MDM4 haploinsufficiency activates p53, causing diverse bone marrow failure phenotypes and hypocellular MDS, highlighting the pivotal MDM4-p53 axis in hematopoietic regulation and potential targets for intervention.

Hematology-Oncology news Oncology

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY 05/27/2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

Clinical Updates news

Curcumin Mitigates Methotrexate-Induced Ovarian Damage: Insights into Antioxidant Protection via PARP-1 and P53 Modulation

By MedXY 08/06/2025

Curcumin pretreatment reduces methotrexate-induced ovarian damage in rats by regulating oxidative stress and apoptosis pathways, highlighting a potential strategy for fertility preservation in chemotherapy.